I have some the interpretation of the "ACE2 and TMPRSS2 polymorphism analysis" paper referred to in your recent interview.
When checking the metadata and not being concerned about race specificity is looking at only immediate death. The paper refers to the polymorphism risk. The polymorphism in the paper is regarding the misfolding and wont show up for some time in the metadata. Background: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904311/
I have some the interpretation of the "ACE2 and TMPRSS2 polymorphism analysis" paper referred to in your recent interview.
When checking the metadata and not being concerned about race specificity is looking at only immediate death. The paper refers to the polymorphism risk. The polymorphism in the paper is regarding the misfolding and wont show up for some time in the metadata. Background: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904311/
This is the paper that was brought up today: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-020-01673-z
Nobody seems to understand this paper correctly. Everyone seems to interpret in terms of acute effects. Incorrect!